Clinical Trial Update: Rituximab in Recurrent IgA Nephropathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update studying Rituximab for recurrent IgA nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Chulalongkorn University | Conditions: Recurrent IgA Nephropathy | Phase 4 | Status: UNKNOWN